Copper is an essential trace element that has been used for millennia by various cultures, such as the Egyptians and Romans, for its antimicrobial properties. This ancient wisdom found a modern advocate in Javier Lavin, whose career began in the retail business. It wasn’t until Lavin worked in the copper mines of northern Chile that he realized copper’s potential extended far beyond traditional applications, like animal feed supplements. He discovered that copper’s natural ability to control bacteria could have transformative implications for food preservation. Lavin's extensive knowledge of the food industry, paired with his expertise in copper, fueled the creation of Copperprotek’s innovative microparticle technology, setting the stage for the company’s breakthrough into the food packaging sector. The Chilean startup is now among the first to commercialize copper microparticles, using them to extend the shelf life of food and revolutionize the packaging industry. “We bring one of nature's oldest antimicrobial agents into the future with our copper-infused packaging, offering a clean and effective way to preserve food quality and extend shelf life,” says Javier Lavin, co-founder of Copperprotek. FDA Approval: A Major Breakthrough for Copper-Based Biotech One of Copperprotek's most significant achievements is securing FDA and USDA approval for its copper-based packaging technology. This landmark approval has positioned Copperprotek as the first company in the world to have copper biotech certified by the FDA. “It’s important to note that while copper is a naturally occurring and well-studied mineral, gaining FDA approval for a food contact material was a rigorous process that took over two years,” says Lavin. .

Intrials stands as a seasoned CRO with a remarkable 25-year journey in the industry. With over 550 successfully concluded studies spanning all phases of clinical development and post-market endeavors, its track record speaks volumes about its commitment to excellence. Under the leadership of Marina Domenech, CEO, the company has experienced significant growth over the past five years. Her visionary guidance has propelled Intrials to new heights, solidifying its position as an industry leader. Operating across six countries in LATAM — Argentina, Brazil (headquarters), Chile, Colombia, Mexico and Peru— Intrials’ regional expertise sets it apart. Its full-service delivery model ensures end-to-end support, from regulatory know-how to establishing connections with leading clinical trial sites and principal investigators (PIs). This local footprint enables Intrials to efficiently navigate sponsor needs. “Working with different therapeutic areas has been part of Intrials’ history since 1999 and has allowed us to enhance our skills to cater to the particular needs of each study. Collaborating seamlessly with pharmaceutical giants and agile biotechs, we’re dedicated to fostering innovation,” says Domenech. At the heart of Intrials’ mission lies a profound commitment to improving public health throughout the LATAM region. By conducting clinical research, it facilitates access of these trials to local patients and contributes to community well-being. Through its endeavors, Intrials not only addresses current healthcare challenges but also paves the way for future breakthroughs, fostering a culture of innovation in clinical research. .